Patent · US Active

Serpina1 iRNA compositions and methods of use thereof

US10030244B2 · kind B2 · utility

6Cited by

1References

28Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Alfica Sehgal · Cambridge, US
Klaus Charisse · Acton, US
Brian Bettencourt · Groton, US
Martin Maier · Cambridge, US
Kallanthottathil G. Rajeev · Wayland, US
Gregory Hinkle · Plymouth, US
Muthiah Manoharan · Carlsbad, US

Key dates

Filing date	Jan 6, 2017
Grant date	Jul 24, 2018
Priority date	—
Expiry date	Jan 6, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2330/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.